Breast cancer, version 3.2013 Journal Article

   


Authors: Theriault, R. L.; Carlson, R. W.; Allred, C.; Anderson, B. O.; Burstein, H. J.; Edge, S. B.; Farrar, W. B.; Forero, A.; Giordano, S. H.; Goldstein, L. J.; Gradishar, W. J.; Hayes, D. F.; Hudis, C. A.; Isakoff, S. J.; Ljung, B. M. E.; Mankoff, D. A.; Marcom, P. K.; Mayer, I. A.; McCormick, B.; Pierce, L. J.; Reed, E. C.; Schwartzberg, L. S.; Smith, M. L.; Soliman, H.; Somlo, G.; Ward, J. H.; Wolff, A. C.; Zellars, R.; Shead, D. A.; Kumar, R.
Article Title: Breast cancer, version 3.2013
Abstract: These NCCN Guidelines Insights highlight the important updates specific to the management of HER2-positive metastatic breast cancer in the 2013 version of the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer. These include new first-line and subsequent therapy options for patients with HER2-positive metastatic breast cancer. Copyright © 2013 by the National Comprehensive Cancer Network. All rights reserved.
Keywords: cancer diagnosis; clinical practice; metastasis; breast cancer; epidermal growth factor receptor 2; practice guideline; oncology; algorithm; taxane derivative; trastuzumab; protein determination; lapatinib; pertuzumab
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 11
Issue: 7
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2013-07-01
Start Page: 753
End Page: 761
Language: English
PROVIDER: scopus
PUBMED: 23847214
PMCID: PMC3991132
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84880964487&partnerID=40&md5=dd45b187db8bc80c8ed4795c56cbdb8c
Notes: --- - Cited By (since 1996):3 - "Export Date: 2 December 2013" - "Source: Scopus"
Citation Impact
What is Dimensions Citation Badge?
MSK Authors
  1. Clifford Hudis
    905 Hudis
  2. Beryl McCormick
    371 McCormick
Related MSK Work